Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.170
-0.090 (-7.14%)
At close: Oct 29, 2026, 4:00 PM EDT
1.130
-0.040 (-3.42%)
Pre-market: Oct 30, 2026, 5:09 AM EDT
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$278,703
Profits / Employee
-$285,214
Market Cap
89.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| ImmuCell | 73 |
| Rani Therapeutics Holdings | 71 |
| Tenaya Therapeutics | 70 |
| Genelux | 26 |
| NeurAxis | 24 |
| Tevogen | 18 |
| Atara Biotherapeutics | 10 |
CLLS News
- 2 days ago - Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 - Nasdaq
- 2 days ago - Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27 - Nasdaq
- 3 days ago - Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 - GlobeNewsWire
- 3 days ago - Cellectis sees FY27 adjusted EPS $21.50 - TheFly
- 3 days ago - Cellectis sees FY27 capital expenditures $1.5B-$2B - TheFly
- 3 days ago - Cellectis sees Q4 adjusted EPS $3.37-$3.57 - TheFly
- 3 days ago - Cellectis raises FY26 adjusted EPS view to $11.55 from $11.30, consensus $11.15 - TheFly
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS - PRNewsWire